India releases first national guidance on nutritional risks of GLP-1 weight-loss drugs

Indian clinicians and nutrition specialists have published the country's first formal advisory on the hidden costs of weight loss achieved through GLP-1 receptor agonists, urging doctors to monitor patients for muscle wasting and micronutrient gaps. The guidance, highlighted by The South First, comes as prescriptions for these once-weekly injections climb rapidly across urban India.

Why the new guidance was needed

Rapid weight loss from GLP-1 drugs such as semaglutide and tirzepatide is often celebrated, but the advisory notes that the pounds shed are not always fat. Without structured nutritional support, patients can lose lean muscle mass alongside adipose tissue, raising long-term concerns about strength, bone health and metabolic rate. The document calls for baseline body-composition scans before treatment begins.

Nutrient deficiencies clinicians are watching

The panel flagged several shortfalls that can emerge when appetite falls sharply and food intake drops:

• Reduced protein intake leading to sarcopenia risk
• Low levels of vitamin B12, vitamin D and iron
• Inadequate fibre and electrolyte balance from skipped meals
• Possible calcium and zinc gaps affecting bone and immune health

What doctors are now advised to do

Endocrinologists and dietitians should pair every prescription with a personalised meal plan emphasising protein density, resistance training and periodic bloodwork. Patients are encouraged to report fatigue, hair shedding or recurring infections, which can signal hidden deficiencies.

The guidance reflects a wider debate over whether modern weight-loss medications are being prescribed without adequate wraparound care, and connects to ongoing research into midlife muscle preservation. It also dovetails with broader concerns about everyday habits that quietly undermine digestive and metabolic wellness.